Syndax Pharmaceuticals Inc (SNDX) Stock Price & Analysis
Syndax Pharmaceuticals Inc (SNDX) fell 1.89% to USD 20.81 as of July 25, 2026 at 03:55 UTC, according to Nexqual real-time market data.
SNDX last closed at USD 21.21; the session ranged USD 20.57–21.44 on volume of 1,181,103 shares. Market capitalization is $1.84B, with a 52-week range of USD 9.42–25.59 (NMS). Source: Nexqual, July 25, 2026 at 03:55 UTC.
Key Statistics (as of July 25, 2026 at 03:55 UTC)
| Price | USD 20.81 |
|---|---|
| Change | ▼ 1.89% (down) |
| Previous Close | USD 21.21 |
| Open | USD 21.38 |
| Day Range | USD 20.57 – 21.44 |
| 52-Week Range | USD 9.42 – 25.59 |
| Volume | 1,181,103 shares |
| Market Cap | $1.84B |
| Exchange | NMS |
Technical Analysis (SNDX)
Nexqual's technical model rates SNDX "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:55 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.65 (neutral) |
| vs SMA50 | Above (USD 20.47) |
| MACD | 0.37 (positive) |
Analyst Ratings (SNDX)
Wall Street analysts rate SNDX "Strong Buy" based on 11 analysts, with a mean price target of USD 39.45 (range USD 29–57), per Nexqual as of July 25, 2026 at 03:55 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 39.45 |
| High Target | USD 57 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (SNDX)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD -0.44 |
| Revenue Estimate | $79.33M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.48 vs est -0.59 ▲ beat |
| 2025-12-31 | USD -0.78 vs est -0.58 ▼ miss |
| 2025-09-30 | USD -0.7 vs est -0.71 ▲ beat |
| 2025-06-30 | USD -0.83 vs est -1.01 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:55 UTC.
Financials & Fundamentals (SNDX)
| Total Revenue | $217.17M |
|---|---|
| Revenue Growth (YoY) | +223.60% |
| Gross Margin | -23.17% |
| Operating Margin | -52.73% |
| Profit Margin | -112.01% |
| ROE | -189.53% |
| Debt / Equity | 829.75 |
| Current Ratio | 5.47 |
| Total Cash | $361.24M |
| Total Debt | $345.36M |
| Free Cash Flow | $-186.01M |
Source: Nexqual, July 25, 2026 at 03:55 UTC.
Financial Health Score (SNDX)
Nexqual rates Syndax Pharmaceuticals Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:55 UTC.
| Growth | Strong — Revenue +628% YoY (annual) |
|---|---|
| Profitability | Critical — Gross margin -23%, operating -53% |
| Balance Sheet | Weak — $361M cash vs $345M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$186M, burning cash |
| Efficiency | Critical — ROE -190%, ROA -25.1% |
Ownership (SNDX)
| Insider Ownership | +1.70% |
|---|---|
| Institutional Ownership | +117.12% |
| Shares Outstanding | 88.61M |
| Float | 79.61M |
| Short % of Float | +25.05% |
Source: Nexqual, July 25, 2026 at 03:55 UTC.
Leadership (SNDX)
Syndax Pharmaceuticals Inc is led by Michael A. Metzger (age 54), CEO & Director, per Nexqual as of July 25, 2026 at 03:55 UTC.
| CEO & Director | Michael A. Metzger (age 54) |
|---|---|
| CFO, Treasurer & Principal Accounting Officer | Keith Alan Goldan (age 54) |
| Co-Founder & Chief Scientific Officer | Peter Ordentlich B.Sc. (age 56) |
| Vice President of Investor Relations & Communications | Sharon Klahre |
Major Backers & Investors (SNDX)
Notable institutional backers of Syndax Pharmaceuticals Inc include Kynam Capital Management, LP, Goldman Sachs, Bank of America Corporation, according to Nexqual as of July 25, 2026 at 03:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kynam Capital Management, LP | 9.09% |
| Goldman Sachs | 5.64% |
| Bank of America Corporation | 4.8% |
| Deerfield Management Company, L.P | 4.27% |
| Eversept Partners, LP | 3.26% |
| Kingdon Capital Management LLC | 2.82% |
| Hood River Capital Management LLC | 2.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.08% |
| State Street | 8.97% |
| Vanguard Group | 8.52% |
Source: Nexqual, July 25, 2026 at 03:55 UTC.
From Syndax Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
- Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
- The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.
- It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KURA | Kura Oncology, Inc. | USD 10.39 | ▼ 1.42% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| REPL | Replimune Group, Inc. | USD 9.7 | ▼ 9.77% |
| RCUS | Arcus Biosciences, Inc. | USD 28.42 | ▼ 5.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:55 UTC. This page is informational and not investment advice.